GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello A/S (STU:4AJ0) » Definitions » Price-to-Owner-Earnings

Alk-Abello A/S (STU:4AJ0) Price-to-Owner-Earnings : 54.09 (As of May. 24, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Alk-Abello A/S Price-to-Owner-Earnings?

As of today (2024-05-24), Alk-Abello A/S's share price is €18.93. Alk-Abello A/S's Owner Earnings per Share (TTM) ended in Mar. 2024 was €0.35. It's Price-to-Owner-Earnings for today is 54.09.


The historical rank and industry rank for Alk-Abello A/S's Price-to-Owner-Earnings or its related term are showing as below:

STU:4AJ0' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 14.36   Med: 75.82   Max: 5812.5
Current: 53.5

During the past 13 years, the highest Price-to-Owner-Earnings of Alk-Abello A/S was 5812.50. The lowest was 14.36. And the median was 75.82.


STU:4AJ0's Price-to-Owner-Earnings is ranked worse than
68.94% of 161 companies
in the Biotechnology industry
Industry Median: 32.4 vs STU:4AJ0: 53.50

As of today (2024-05-24), Alk-Abello A/S's share price is €18.93. Alk-Abello A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.34. Therefore, Alk-Abello A/S's PE Ratio for today is 56.51.

As of today (2024-05-24), Alk-Abello A/S's share price is €18.93. Alk-Abello A/S's EPS without NRI for the trailing twelve months (TTM) ended in was €0.34. Therefore, Alk-Abello A/S's PE Ratio without NRI for today is 56.51.

During the past 13 years, Alk-Abello A/S's highest PE Ratio without NRI was 1234.51. The lowest was 22.39. And the median was 61.05.


Alk-Abello A/S Price-to-Owner-Earnings Historical Data

The historical data trend for Alk-Abello A/S's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello A/S Price-to-Owner-Earnings Chart

Alk-Abello A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 125.39 86.05 51.16

Alk-Abello A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 86.05 126.20 94.65 51.16 44.02

Competitive Comparison of Alk-Abello A/S's Price-to-Owner-Earnings

For the Biotechnology subindustry, Alk-Abello A/S's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alk-Abello A/S's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello A/S's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Alk-Abello A/S's Price-to-Owner-Earnings falls into.



Alk-Abello A/S Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Alk-Abello A/S's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=18.93/0.35
=54.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alk-Abello A/S  (STU:4AJ0) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Alk-Abello A/S Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Alk-Abello A/S's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Alk-Abello A/S (STU:4AJ0) Business Description

Address
Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello A/S is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication.

Alk-Abello A/S (STU:4AJ0) Headlines

No Headlines